The latest price target for Tempest Therapeutics (NASDAQ:TPST) was reported by HC Wainwright & Co. on August 15, 2024. The analyst firm set a price target for $47.00 expecting TPST to rise to within 12 months (a possible 3600.79% upside). 11 analyst firms have reported ratings in the last year.

The latest analyst rating for Tempest Therapeutics (NASDAQ:TPST) was provided by HC Wainwright & Co., and Tempest Therapeutics reiterated their buy rating.

There is no last upgrade for Tempest Therapeutics

There is no last downgrade for Tempest Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tempest Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tempest Therapeutics was filed on August 15, 2024 so you should expect the next rating to be made available sometime around August 15, 2025.

While ratings are subjective and will change, the latest Tempest Therapeutics (TPST) rating was a reiterated with a price target of $47.00 to $47.00. The current price Tempest Therapeutics (TPST) is trading at is $1.27, which is out of the analyst’s predicted range.